|
- What Is Cancer? - NCI
Explanations about what cancer is, how cancer cells differ from normal cells, and genetic changes that cause cancer to grow and spread
- HPV and Pap Test Results: Next Steps after an Abnormal Test
Although CIN 3 is not cancer, it may become cancer and spread to nearby normal tissue if not treated Doctors do not yet have a way to tell which cases of CIN 3 will become cancer and which will not
- GDC Data Portal Homepage
High-quality datasets spanning cases from cancer genomic studies such as The Cancer Genomic Atlas (TCGA), Human Cancer Models Initiative (HCMI), Foundation Medicine Inc (FMI), and Clinical Proteomic Tumor Analysis Consortium (CPTAC)
- 2025 Solid Tumor Rules - SEER Tools
SRP provides national leadership in the science of cancer surveillance as well as analytical tools and methodological expertise in collecting, analyzing, interpreting, and disseminating reliable population-based statistics
- SEER*Rx - Cancer Registrars Interactive Antineoplastic Drugs Database . . .
SEER*Rx was developed as a one-step lookup for coding oncology drug and regimen treatment categories in cancer registries The information in this database is effective for cancer diagnoses made on January 1, 2005 and after
- CTCAE and AE Reporting - NCI - dctd. cancer. gov
Accurate and specific reporting of adverse events (AE) in clinical trials is critical to protecting patients and accurately determining the effects of new cancer treatments
- Rifaximin versus No Intervention for the Treatment of IgA Monoclonal . . .
Rifaximin is a type of antibiotic that is only used in cancer chemotherapy (antineoplastic antibiotic) It works by damaging the cell’s DNA and may kill cancer cells or precancerous cells like those found with MGUS Giving rifaximin may kill more precancerous cells in patients with IgA MGUS
- SEER Data Software
Use SEER data to address multiple topics; for example, you can: Examine stage at diagnosis by race ethnicity Calculate survival by stage at diagnosis, age at diagnosis, and tumor grade or size Determine trends and incidence rates for various cancer sites over time
|
|
|